Agenus/$AGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Agenus
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Ticker
$AGEN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
316
ISIN
US00847G8042
Website
Agenus Metrics
BasicAdvanced
$97M
-
-$8.48
1.48
-
Price and volume
Market cap
$97M
Beta
1.48
52-week high
$19.69
52-week low
$1.38
Average daily volume
892K
Financial strength
Current ratio
0.111
Quick ratio
0.09
Long term debt to equity
-26.932
Total debt to equity
-28.549
Interest coverage (TTM)
-1.01%
Management effectiveness
Return on assets (TTM)
-28.70%
Return on equity (TTM)
76.14%
Valuation
Price to revenue (TTM)
0.803
Price to book
-0.28
Price to tangible book (TTM)
-0.26
Price to free cash flow (TTM)
-0.546
Growth
Revenue change (TTM)
-38.34%
Earnings per share change (TTM)
-32.67%
3-year revenue growth (CAGR)
-31.52%
3-year earnings per share growth (CAGR)
76.46%
What the Analysts think about Agenus
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Agenus Financial Performance
Revenues and expenses
Agenus Earnings Performance
Company profitability
Agenus News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agenus stock?
Agenus (AGEN) has a market cap of $97M as of May 28, 2025.
What is the P/E ratio for Agenus stock?
The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of May 28, 2025.
Does Agenus stock pay dividends?
No, Agenus (AGEN) stock does not pay dividends to its shareholders as of May 28, 2025.
When is the next Agenus dividend payment date?
Agenus (AGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Agenus?
Agenus (AGEN) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.